Core Viewpoint - Metagenomi, Inc. is actively participating in the TD Cowen's 45th Annual Health Care Conference, showcasing its commitment to developing curative therapeutics through its proprietary gene editing toolbox [1]. Company Overview - Metagenomi is a precision genetic medicines company focused on curative therapeutics using an AI-driven metagenomics platform [3]. - The company leverages four billion years of microbial evolution to discover novel editing tools capable of correcting any genetic mutation in the genome [3]. - Its genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and CAST [3]. - Metagenomi's proprietary toolbox is designed to access the entire genome and select optimal tools for effective genome editing [3]. Event Participation - Brian C. Thomas, PhD, CEO and founder of Metagenomi, will engage in a fireside chat at the conference on March 5, 2025, from 1:10-1:40 p.m. ET in Boston [1]. - The company will also host one-on-one investor meetings during the conference [1].

Core Insights - Metagenomi, Inc. is advancing its gene editing candidate MGX-001 for hemophilia A, with regulatory interactions anticipated in 2025 and a focus on achieving proof-of-concept for secreted protein deficiencies [1][2][6] - The company is on track to nominate one to two development candidates from its collaboration with Ionis in 2025, targeting large cardiometabolic indications [1][12] - Metagenomi's cash runway is expected to support its operational plans into 2027, indicating financial stability for ongoing projects [1] Hemophilia A Program - MGX-001 has achieved sustained Factor VIII (FVIII) activity in a nonhuman primate study over 16 months, demonstrating its potential efficacy [6] - The company has engaged with the FDA for initial regulatory discussions and has initiated GxP manufacturing activities for MGX-001 [6] - Plans for 2025 include finalizing the ongoing nonhuman primate durability study and continuing Investigational New Drug (IND) enabling efforts [6] Secreted Protein Deficiencies - In 2024, Metagenomi identified targets for wholly-owned therapeutic programs leveraging the albumin approach used in MGX-001 [4] - The company anticipates demonstrating proof-of-concept for its lead secreted protein deficiency target in nonhuman primates in 2025 [7] Cardiometabolic Programs - Metagenomi has advanced all four Wave 1 Ionis collaboration programs to lead optimization, achieving in vivo proof-of-concept in rodents [12] - The company plans to nominate development candidates from these programs in 2025 and disclose remaining therapeutic indications [12] Technology Development - Metagenomi has made advancements in its gene editing toolbox, including next-generation base editors and ultra-small nucleases [2][12] - The company presented novel Adenine Base Editors (ABEs) that target over 95% of the human genome, demonstrating high specificity and no adverse effects on cell health [12]

Core Insights - Metagenomi, Inc. announced the appointment of Eric Bjerkholt, CFO of Mirum Pharmaceuticals, to its Board of Directors, effective January 27, 2025 [1][2] - Bjerkholt's extensive experience in the pharmaceutical industry and business development is expected to enhance Metagenomi's efforts in developing curative genetic therapies [2] - Metagenomi utilizes a proprietary metagenomics-derived toolbox to create precision genetic medicines, aiming to correct genetic mutations across the genome [3] Company Overview - Metagenomi is focused on developing curative therapeutics using a comprehensive toolbox derived from metagenomics, which studies genetic material from the environment [3] - The company's toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, positioning it to access the entire genome for optimal editing solutions [3] Leadership Experience - Eric Bjerkholt has a strong background in financial leadership, having served as CFO at multiple pharmaceutical companies, including Mirum Pharmaceuticals and Chinook Therapeutics [2] - His previous roles include overseeing financial reporting, planning, budgeting, and investor relations, contributing to his capability to support Metagenomi's strategic goals [2]

Core Viewpoint - Metagenomi, Inc. is set to present at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its commitment to developing curative therapeutics through its proprietary gene editing toolbox [1]. Company Overview - Metagenomi is a precision genetic medicines company focused on curative therapeutics using a comprehensive metagenomics-derived toolbox [3]. - The company utilizes metagenomics to explore four billion years of microbial evolution, aiming to discover novel editing tools for correcting genetic mutations across the genome [3]. - Its genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and CAST [3]. - Metagenomi believes its diverse and modular toolbox allows access to the entire genome, optimizing genome editing potential for patients [3]. Event Details - Brian C. Thomas, PhD, CEO and founder of Metagenomi, will present on January 15, 2025, at 4:30 p.m. PT in San Francisco [1]. - A live webcast of the presentation will be available on the company's investor website, with a replay accessible for a limited time [2].

Core Insights - Metagenomi, Inc. is focused on developing curative therapeutics using its proprietary gene editing toolbox, emphasizing the precision and safety of its technologies [1][2][3] Group 1: Gene Editing Technologies - MGX-001, a candidate for hemophilia A, utilizes the MG29-1 nuclease and shows no identifiable off-target editing, confirmed through various assays [2] - The MG29-1 nuclease targeting the albumin safe harbor locus demonstrated no evidence of translocations in primary human hepatocytes [2] - Metagenomi's adenine base editor (ABE) for ex vivo cell therapy showed no detectable translocations and no significant genomic base composition differences in primary T-cells compared to unedited cells [2] Group 2: Company Overview - Metagenomi leverages metagenomics to develop a comprehensive toolbox for genome editing, which includes programmable nucleases, base editors, and integration systems [3] - The company aims to correct any type of genetic mutation found in the genome, utilizing four billion years of microbial evolution [3] - Metagenomi's diverse and modular toolbox is designed to access the entire genome and select optimal tools for effective genome editing [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Metagenomi stock between February 9 and 13, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 25, 2024 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Company Background and Allegations - Metagenomi, described as a "genetic medicines company," had a collaboration with Moderna, which was highlighted during its IPO [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at $15 per share [4] - The collaboration with Moderna was terminated on May 1, 2024, leading to claims that investors suffered damages when the true details were revealed [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Metagenomi stock during the IPO from February 9 to 13, 2024, may be eligible for compensation without any out-of-pocket costs through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 25, 2024 [2][5] - The lawsuit claims that investors suffered damages after Metagenomi announced the termination of its collaboration with Moderna, which was a key aspect of its IPO presentation [4] Group 2: Company Background - Metagenomi is described as a "genetic medicines company" that had a significant collaboration with Moderna, including a Strategic Collaboration and License Agreement established on October 29, 2021 [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [4]

Core Viewpoint - A securities class action lawsuit has been filed against Metagenomi Inc. for allegedly misleading investors regarding its business prospects and relationship with Moderna during the specified Class Period from February 6, 2024, to September 26, 2024 [1]. Company Overview - Metagenomi is a genetic medicines company based in Emeryville, CA, with a significant collaboration with Moderna, a leading Covid-19 vaccine company [3]. - The collaboration included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple four-year research programs [3]. IPO and Stock Performance - Metagenomi completed its initial public offering (IPO) on February 13, 2024, selling 6.25 million shares at $15 per share [4]. - Following the announcement of the termination of the collaboration with Moderna on May 1, 2024, Metagenomi's shares dropped from $7.04 to $6.17 within a day and continued to decline, trading slightly above $2.00 at the time of the lawsuit filing [5].

Core Viewpoint - Metagenomi, Inc. is facing a class action lawsuit following the termination of its collaboration with Moderna, which was a significant aspect of its initial public offering narrative [3]. Group 1: Company Background - Metagenomi, Inc. is characterized as a "genetic medicines company" and had a strategic collaboration with Moderna, a leading Covid-19 vaccine company [3]. - The company completed its initial public offering on February 13, 2024, selling 6.25 million shares at $15 per share [3]. Group 2: Allegations and Impact - The lawsuit alleges that Metagenomi misled investors regarding its collaboration with Moderna, which was critical to its business model [3]. - Following the announcement of the termination of the collaboration on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 within a day, indicating a significant market reaction to the news [3]. Group 3: Legal Proceedings - Shareholders who purchased shares during the class period from February 9 to 13, 2024, are encouraged to register for the class action lawsuit [2][4]. - The deadline for shareholders to seek lead plaintiff status is November 25, 2024 [4].

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi’s registration statement for the initial public offering held between F ...